ORYZON shareholders approve listing to the Spanish Continuous Market

- Company to submit prospectus in Q4-2015
- Solventis AV investment banking will coordinate the IPO process

BARCELONA / CAMBRIDGE, MA

The General Meeting of Shareholders of Oryzon, a clinical stage biopharmaceutical company focused on Epigenetics to develop therapies in oncology and neurodegenerative diseases, agreed to publicly trade 100% of the company’s shares in the Spanish Main Market.

Click here to see the full Press Release.